Study analysis · Brain, behavior, and immunity · 2024
Your brain has tiny garbage collectors that could be the key to stopping severe seizures—and scientists just found out what happens when they malfunction.
Mice missing a protein called TREM2 have worse seizures because their brain's immune cells can't clean up damaged neurons properly, and humans with less of this cleaning activity also have more severe seizures.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at mice that were missing a special protein in their brain's clean-up cells. They found that without this protein, the mice had more seizures and their brain cells weren't being cleared as well. They also looked at brain tissue from people with epilepsy and found that a marker for clean-up activity was lower in people who had more severe seizures. But this is like noticing that people who eat a lot of ice cream also go to the beach—it doesn't mean ice cream causes beach trips. So we can only say there's a connection, not that one causes the other.
What’s the bottom line?
The brain has special immune cells called microglia that act like garbage collectors, clearing away damaged cells after seizures. A protein called TREM2 helps these cells do their job. In mice lacking TREM2, seizures are worse and the brain can't clear damaged neurons properly. In patients with epilepsy, less of this cleaning activity is linked to a history of more severe seizures.
How strong is this study?
The study did many careful measurements and used both mice and human samples, which is good. But the scientists weren't sure if they were blinded (like keeping the test scores hidden), and they only used male mice, which might not be like all mice. The human part was just a look at tissue after surgery, not following patients over time. So the results are a clue, but not a final answer.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 511 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This study combines an experimental animal model (TREM2 knockout mice) with a cross-sectional analysis of human tissue. While the animal model involves controlled genetic manipulation, it is not a randomized controlled trial and has limited translatability to humans. The human tissue analysis is observational and cross-sectional, which cannot establish cause-and-effect relationships. Therefore, this study cannot establish causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed in the study text.
Independent Analysis Safeguards
- RNA sequencing was performed by an external service (BGI).
The study notes that investigators were not blinded during data collection or analysis, which could introduce bias. Only male mice were used. Human tissue was obtained from Mayo Clinic Tissue Registry with IRB approval.
Key takeaways
- 01
Mice without TREM2 had more seizures and their microglia were less able to engulf dying neurons.
- 02
In humans, lower levels of a phagocytosis marker (CD68) in brain tissue were associated with having had generalized seizures.
- 03
Yes, the results are significant because they suggest that enhancing microglial phagocytosis might reduce seizure severity in epilepsy.
Surprising findings
- TREM2 knockout mice had more severe acute seizures and more spontaneous recurrent seizures, contrary to the idea that microglial activation is always harmful.Conventional wisdom in epilepsy research often suggests that microglial activation contributes to inflammation and exacerbates seizures. This study shows that a specific microglial function (phagocytosis) is actually protective.
- The reduction in microglial proliferation and reactive morphology in TREM2 KO mice did not affect the initial recognition of apoptotic cells, but impaired the actual engulfment later on.It was expected that TREM2 deficiency would impair early phagocytosis, but the study found that initial contact was normal; instead, the completion of engulfment was severely reduced (25% vs. 5.2% at day 7).
- Human tissue showed that CD68 expression was predominantly in white matter, not gray matter, suggesting that microglia might sever nerve connections to prevent seizure spread.Most research focuses on gray matter damage, but this study suggests that white matter microglial activity might be key to limiting generalized seizures.
Practical takeaways
For epilepsy patients, ask your doctor about potential future therapies that target microglial function or TREM2, as this research suggests enhancing phagocytosis might reduce seizure severity.
This is early-stage research; no clinical treatments are available yet. Always follow current medical advice.
medium confidenceResearchers can use these findings to develop TREM2 agonists or other drugs that boost microglial phagocytosis as a potential treatment for epilepsy.
Animal model results may not translate directly to humans; more studies needed.
medium confidenceFor content creators, explain that epilepsy isn't just about neurons; immune cells like microglia play a huge role, and this opens up new research avenues.
Be careful not to overstate the findings; it's a single study.
high confidenceWhy this study matters
Microglia: The Brain's Unsung Heroes
Microglia are the brain's resident immune cells, acting as garbage collectors to clear dead and dying neurons after injury. This study shows that when they can't do their job due to TREM2 deficiency, seizures become more severe and frequent. In mice lacking TREM2, the number of spontaneous recurrent seizures was higher, and microglial engulfment of dying neurons dropped from 25% to only 5.2% at 7 days post-seizure.
Most people never hear about microglia, but they play a vital role in brain health. This study reveals that boosting their cleaning power could be a new way to treat epilepsy, affecting millions worldwide.
TREM2: A Seizure-Suppressing Protein?
TREM2 is a protein found on microglia that helps them sense damage and activate. In this study, mice without TREM2 had more acute seizures and more chronic spontaneous seizures after a chemically induced seizure. The study found that TREM2 is crucial for microglial proliferation, adopting a reactive shape, and phagocytosing damaged neurons.
This suggests that TREM2 is not just a player in Alzheimer's, as previously known, but also in epilepsy. It opens up a new avenue for drug development targeting TREM2 to potentially reduce seizure severity.
Human Connection: Lower CD68, More Severe Seizures
In brain tissue from 31 patients with drug-resistant epilepsy, researchers found that lower expression of CD68, a marker of microglial phagocytic activity, was linked to a history of focal to bilateral tonic-clonic seizures (generalized seizures). This mirrors the mouse findings, suggesting the protective role of microglial cleaning may apply to humans.
It's a direct correlation in humans, which increases the relevance of the animal findings. It hints that we might be able to predict or treat seizure generalization by boosting microglial activity.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
The brain has special immune cells called microglia that act like garbage collectors, clearing away damaged cells after seizures. A protein called TREM2 helps these cells do their job. In mice lacking TREM2, seizures are worse and the brain can't clear damaged neurons properly. In patients with epilepsy, less of this cleaning activity is linked to a history of more severe seizures.
Research results
Mice without TREM2 had more seizures and their microglia were less able to engulf dying neurons. In humans, lower levels of a phagocytosis marker (CD68) in brain tissue were associated with having had generalized seizures.
What this means - more context
Yes, the results are significant because they suggest that enhancing microglial phagocytosis might reduce seizure severity in epilepsy.
To determine the role of microglial TREM2 in seizure development and epileptogenesis.
Using TREM2 knockout (KO) mice in the intra-amygdala kainic acid (KA) seizure model, the study found that TREM2 deficiency increased the severity of acute status epilepticus and the frequency of spontaneous recurrent seizures. TREM2 KO impaired microglial proliferation, adoption of amoeboid morphology, and phagocytic clearance of damaged neurons. RNAseq revealed reduced upregulation of cell cycle and disease-associated microglia genes. In human temporal lobe tissue from drug-resistant epilepsy patients, lower CD68 expression (phagocytic marker) correlated with a history of focal to bilateral tonic-clonic seizures.
Methods Used
Male TREM2 KO and control mice (CX3CR1-GFP) underwent intra-amygdala KA administration. Seizure behavior and EEG were monitored. Microglial response was assessed via immunofluorescence (Iba1, CD68, BrdU, PSVue), Fluoro-Jade C staining, and in vitro phagocytosis assay. RNAseq was performed on CD11b-sorted microglia. Human temporal lobe and hippocampal sections from 31 drug-resistant epilepsy patients were stained for Iba1 and CD68.
Main Finding
TREM2 deficiency exacerbates seizure severity and epileptogenesis, likely due to impaired microglial phagocytosis of damaged neurons, as supported by mouse and human data.
Confidence Level
Moderate: robust animal model with multiple complementary methods, but human correlation is correlational and only male mice were used.
Study Flags
Red Flags
- •Only male mice were used; female mice not tested.
- •Investigators were not blinded during data collection or analysis.
- •Human sample size is relatively small (N=31) and tissue is from surgical resections, which may not be representative.
Surprising Findings
TREM2 knockout mice had more severe acute seizures and more spontaneous recurrent seizures, contrary to the idea that microglial activation is always harmful.
Conventional wisdom in epilepsy research often suggests that microglial activation contributes to inflammation and exacerbates seizures. This study shows that a specific microglial function (phagocytosis) is actually protective.
Practical Takeaways
For epilepsy patients, ask your doctor about potential future therapies that target microglial function or TREM2, as this research suggests enhancing phagocytosis might reduce seizure severity.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 511 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice that were missing a special protein in their brain's clean-up cells. They found that without this protein, the mice had more seizures and their brain cells weren't being cleared as well. They also looked at brain tissue from people with epilepsy and found that a marker for clean-up activity was lower in people who had more severe seizures. But this is like noticing that people who eat a lot of ice cream also go to the beach—it doesn't mean ice cream causes beach trips. So we can only say there's a connection, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Use of a well-established intra-amygdala kainic acid seizure model
- Multiple complementary methods including behavioral assessments, EEG, histology, RNAseq, and phagocytosis assays
- Inclusion of human tissue analysis to test relevance across species
Weaknesses
- No randomization; animals were assigned based on genotype, not random allocation
- Blinding was not reported
- Small sample sizes, especially in human tissue analysis
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
The brain has special immune cells called microglia that act like garbage collectors, clearing away damaged cells after seizures. A protein called TREM2 helps these cells do their job. In mice lacking TREM2, seizures are worse and the brain can't clear damaged neurons properly. In patients with epilepsy, less of this cleaning activity is linked to a history of more severe seizures.
Research results
Mice without TREM2 had more seizures and their microglia were less able to engulf dying neurons. In humans, lower levels of a phagocytosis marker (CD68) in brain tissue were associated with having had generalized seizures.
What this means - more context
Yes, the results are significant because they suggest that enhancing microglial phagocytosis might reduce seizure severity in epilepsy.
To determine the role of microglial TREM2 in seizure development and epileptogenesis.
Using TREM2 knockout (KO) mice in the intra-amygdala kainic acid (KA) seizure model, the study found that TREM2 deficiency increased the severity of acute status epilepticus and the frequency of spontaneous recurrent seizures. TREM2 KO impaired microglial proliferation, adoption of amoeboid morphology, and phagocytic clearance of damaged neurons. RNAseq revealed reduced upregulation of cell cycle and disease-associated microglia genes. In human temporal lobe tissue from drug-resistant epilepsy patients, lower CD68 expression (phagocytic marker) correlated with a history of focal to bilateral tonic-clonic seizures.
Methods Used
Male TREM2 KO and control mice (CX3CR1-GFP) underwent intra-amygdala KA administration. Seizure behavior and EEG were monitored. Microglial response was assessed via immunofluorescence (Iba1, CD68, BrdU, PSVue), Fluoro-Jade C staining, and in vitro phagocytosis assay. RNAseq was performed on CD11b-sorted microglia. Human temporal lobe and hippocampal sections from 31 drug-resistant epilepsy patients were stained for Iba1 and CD68.
Main Finding
TREM2 deficiency exacerbates seizure severity and epileptogenesis, likely due to impaired microglial phagocytosis of damaged neurons, as supported by mouse and human data.
Confidence Level
Moderate: robust animal model with multiple complementary methods, but human correlation is correlational and only male mice were used.
Study Flags
Red Flags
- •Only male mice were used; female mice not tested.
- •Investigators were not blinded during data collection or analysis.
- •Human sample size is relatively small (N=31) and tissue is from surgical resections, which may not be representative.
Surprising Findings
TREM2 knockout mice had more severe acute seizures and more spontaneous recurrent seizures, contrary to the idea that microglial activation is always harmful.
Conventional wisdom in epilepsy research often suggests that microglial activation contributes to inflammation and exacerbates seizures. This study shows that a specific microglial function (phagocytosis) is actually protective.
Practical Takeaways
For epilepsy patients, ask your doctor about potential future therapies that target microglial function or TREM2, as this research suggests enhancing phagocytosis might reduce seizure severity.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 511 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice that were missing a special protein in their brain's clean-up cells. They found that without this protein, the mice had more seizures and their brain cells weren't being cleared as well. They also looked at brain tissue from people with epilepsy and found that a marker for clean-up activity was lower in people who had more severe seizures. But this is like noticing that people who eat a lot of ice cream also go to the beach—it doesn't mean ice cream causes beach trips. So we can only say there's a connection, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Use of a well-established intra-amygdala kainic acid seizure model
- Multiple complementary methods including behavioral assessments, EEG, histology, RNAseq, and phagocytosis assays
- Inclusion of human tissue analysis to test relevance across species
Weaknesses
- No randomization; animals were assigned based on genotype, not random allocation
- Blinding was not reported
- Small sample sizes, especially in human tissue analysis
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study did many careful measurements and used both mice and human samples, which is good. But the scientists weren't sure if they were blinded (like keeping the test scores hidden), and they only used male mice, which might not be like all mice. The human part was just a look at tissue after surgery, not following patients over time. So the results are a clue, but not a final answer.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 511 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This study combines an experimental animal model (TREM2 knockout mice) with a cross-sectional analysis of human tissue. While the animal model involves controlled genetic manipulation, it is not a randomized controlled trial and has limited translatability to humans. The human tissue analysis is observational and cross-sectional, which cannot establish cause-and-effect relationships. Therefore, this study cannot establish causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed in the study text.
Independent Analysis Safeguards
- RNA sequencing was performed by an external service (BGI).
The study notes that investigators were not blinded during data collection or analysis, which could introduce bias. Only male mice were used. Human tissue was obtained from Mayo Clinic Tissue Registry with IRB approval.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Siim Land cite this study, drawing 1 claim from it.
- Indication only
Weak evidence — fewer than 20 studies, so treat this as a starting point, not a fact.
Evidence